DURHAM, N.C. & LIEGE, Belgium--(BUSINESS WIRE)--MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, announced today that its licensing partner Exact Sciences Corp. (Nasdaq: EXAS) has initiated a large pivotal trial for Cologuard™, its non-invasive, stool-based DNA colon cancer screening test. Exact confirmed that it is using an MDxHealth methylation biomarker together with MDxHealth’s methylation specific PCR (MSP) platform in Cologuard.
